Eshelman Ventures

Fred Eshelman makes investment decisions as the founder and sole named principal. He typically serves on the boards of portfolio companies directly. The firm does not list any other investment partners or committee members on its website.

The firm does not publicly detail its sourcing model. Given Eshelman’s career as a pharmaceutical executive and his board roles with companies like PPD, Furiex, and The Medicines Company, deal flow likely originates from his professional network within the biopharmaceutical industry and academic research institutions.

The firm states it invests through multiple channels: angel investing in startups, co-investing alongside venture capital funds, committing to private equity funds on the primary and secondary markets, backing academic spinouts, and allocating to hedge funds. It does not publish the ratio of direct to fund commitments.

The firm targets early-stage companies, including seed and startup phases. Its portfolio includes preclinical and clinical-stage biotech companies, indicating a willingness to invest from very early development through to later-stage clinical assets.

The firm’s stated focus is healthcare companies, and its disclosed portfolio is almost exclusively biotechnology and pharmaceuticals. There is no indication that it invests in sectors such as consumer technology, financial services, or industrial technology, with the exception of one 3D printing company, Carbon.

The UNC Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill was named in May 2008 in recognition of Fred Eshelman’s contributions as a donor and board chair. The school is a philanthropic beneficiary of Eshelman personally, but there is no formal investment mandate linking Eshelman Ventures to the university’s research commercialization, although the firm does invest in academic spinouts.

Fred Eshelman’s wealth derives from the sale of Pharmaceutical Product Development (PPD), which he founded and led as CEO and Executive Chairman until its sale to private equity, and from Furiex Pharmaceuticals, a drug-development company he chaired that was sold to Forest Labs/Actavis in July 2014.